Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01391325 · ClinicalTrials.gov registry record · Phase 4
Allopurinol Outcome Study
A Phase 4 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,735
- Enrollment target
NCT01391325 is a Phase 4 study that has completed, run by Ardea Biosciences. The registered enrollment target is 1,735 participants.
The verdict
NCT01391325, a Phase 4 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,735 participants
- Enrollment target
Study Summary
This is a study of allopurinol in gout patients with hyperuricemia that will evaluate the safety and serum urate (sUA) lowering capability of allopurinol as a urate lowering therapy (ULT) for up to six months. Allopurinol will be dosed according to the local product label, at the discretion of the Investigator, to achieve an optimal, medically appropriate dose for each patient.
Interventions
- DRUG Allopurinol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,735 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01391325
The ClinicalTrials.gov registry entry for NCT01391325 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,735 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allopurinol is the first listed.
NCT01391325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01391325 about?
NCT01391325 is a clinical study titled "Allopurinol Outcome Study". This is a study of allopurinol in gout patients with hyperuricemia that will evaluate the safety and serum urate (sUA) lowering capability of allopurinol as a urate lowering therapy (ULT) for up to six months. Allopurinol will be dosed according to the local product label, at the discretion of the I...
What is the current status of trial NCT01391325?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,735 participants. The study started on 2011-07. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01391325?
The interventions under investigation include: Allopurinol (DRUG).
Who is sponsoring clinical trial NCT01391325?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.